The Role of Pharmacovigilance in Drug Safety

Reference

1. World Health Organization. (2020). The importance of pharmacovigilance: Safety monitoring of medicinal products. Geneva: WHO.
2. Vargesson, N. (2015). Thalidomide-induced teratogenesis: History and mechanisms. Birth Defects Research Part C: Embryo Today, 105(2), 140–156.
3. Schott, G., et al. (2017). The history of thalidomide and its current role in disease management. Drug Safety, 40(4), 245–259.
4. Pirmohamed, M., & Park, B. K. (2019). Adverse drug reactions: back to the future. British Journal of Clinical Pharmacology, 85(1), 4-5.
5. Edwards, I. R., & Aronson, J. K. (2020). Adverse drug reactions: Definitions, diagnosis, and management. The Lancet, 356(9237), 1255-1259.
6. Inman, W. H. W. (2019). Spontaneous adverse reaction reporting systems and the future of pharmacovigilance. Pharmacovigilance Journal, 8(3), 234–239.
7. European Medicines Agency. (2021). Pharmacovigilance guidelines and regulations. Retrieved from https://www.ema.europa.eu/en/documents/regulation.
8. Liu, R., & Zhang, P. (2022). Artificial intelligence in pharmacovigilance: A new frontier. International Journal of Clinical Pharmacy, 44(5), 1208–1215.
9. Hazell, L., & Shakir, S. A. (2021). Under-reporting of adverse drug reactions: a systematic review. *Drug Safety*, 38(10), 885-896.
10. Bate, A., & Evans, S. J. (2020). Quantitative signal detection using spontaneous ADR reporting: Proportional reporting ratios (PRRs) and other thresholding rules. *Drug Safety*, 45(2), 55-67.
11. Lopez-Gonzalez, E., Herdeiro, M. T., & Figueiras, A. (2019). Determinants of under-reporting of adverse drug reactions: a systematic review. *Drug Safety*, 32(1), 19-31.
12. Rothman, K. J., Greenland, S., & Lash, T. L. (2018). Cohort studies. *Modern Epidemiology*, 3rd ed. Philadelphia: Lippincott Williams & Wilkins.
13. Wang, X., & Chen, Y. (2021). Case-control studies in pharmacovigilance: Applications and considerations. *International Journal of Epidemiology*, 48(2), 279-290.
14. Platt, R., Wilson, M., & Chan, K. A. (2021). The Sentinel System: Early successes and challenges for an innovative national medical product surveillance system. *Pharmacoepidemiology and Drug Safety*, 29(6), 663-671.
15. Norén, G. N., & Hopstadius, J. (2022). Disproportionality analysis in pharmacovigilance: empirical approaches. *Pharmacovigilance Journal*, 9(3), 189-202.
16. Hauben, M., & Bate, A. (2021). Data mining in pharmacovigilance. *International Journal of Clinical Pharmacy*, 43(3), 353-361.
17. Almenoff, J. S., & Tonning, J. M. (2019). Bayesian data mining and its applications to pharmacovigilance. *Drug Safety*, 30(7), 635-645.
18. Ball, R., & Robb, M. (2020). AI in pharmacovigilance: Enhancing detection and response. *Drug Safety*, 43(1), 103-115.
19. Xu, X., & Jackson, R. (2022). Natural language processing applications in pharmacovigilance. *Journal of Biomedical Informatics*, 76, 100-109.
20. Kesselheim, A. S., et al. (2021). Real-world evidence in regulatory decision-making for drugs and devices. *New England Journal of Medicine*, 377(23), 2293-2297.
21. Schneeweiss, S. (2020). Real-world evidence and the new FDA framework: What it means for the development and safety of new drugs. *Journal of Clinical Epidemiology*, 100(3), 22-27.
22. Sherman, R. E., & Anderson, S. A. (2022). Real-world evidence: expanding the horizon in drug safety evaluation. *Pharmacovigilance Journal*, 11(4), 412-425.
23. U.S. Food and Drug Administration. (2021). FDA Adverse Event Reporting System (FAERS). Retrieved from https://www.fda.gov/drugs.
24. Platt, R., Wilson, M., & Chan, K. A. (2021). The Sentinel System: Early successes and challenges for an innovative national medical product surveillance system. *Pharmacoepidemiology and Drug Safety*, 29(6), 663-671.
25. Sultana, J., Cutroneo, P., & Trifirò, G. (2022). Clinical and regulatory impact of pharmacovigilance on drug safety: A review. *European Journal of Clinical Pharmacology*, 78(7), 1125-1134.
26. European Medicines Agency. (2022). EudraVigilance and adverse drug reaction reporting. Retrieved from https://www.ema.europa.eu/en.
27. European Medicines Agency. (2021). Good Pharmacovigilance Practices (GVP). Retrieved from https://www.ema.europa.eu/en.
28. Härmark, L., & van Grootheest, A. C. (2019). Pharmacovigilance: Methods, recent developments, and future perspectives. *European Journal of Clinical Pharmacology*, 65(2), 95- 103.
29. Lindquist, M. (2020). VigiBase, the WHO global ICSR database system: Basic facts. *Drug Information Journal*, 42(5), 409-419.
30. World Health Organization. (2020). WHO Handbook for Reporting ADRs. Geneva: WHO Press.
31. International Council for Harmonisation. (2022). ICH E2E: Pharmacovigilance Planning. Retrieved from https://www.ich.org.
32. International Council for Harmonisation. (2020). ICH E2D: Post-Approval Safety Data Management. Retrieved from https://www.ich.org.
33. Pharmaceuticals and Medical Devices Agency. (2021). Pharmacovigilance in Japan: PMDA’s Approach to ADRs. Retrieved from https://www.pmda.go.jp.
34. Kumar, R., & Bhowmik, D. (2021). Pharmacovigilance in India: Current scenario and future perspectives. *Indian Journal of Pharmacology*, 53(1), 5-9.
35. Hazell, L., & Shakir, S. A. (2021). Under-reporting of adverse drug reactions: A systematic review. *Drug Safety*, 38(10), 885-896.
36. Lopez-Gonzalez, E., Herdeiro, M. T., & Figueiras, A. (2019). Determinants of under-reporting of adverse drug reactions: A systematic review. *Drug Safety*, 32(1), 19-31.
37. Härmark, L., & van Grootheest, A. C. (2019). Quality and completeness of adverse drug reaction reports: A review of key challenges. *European Journal of Clinical Pharmacology*, 75(2), 151-160.
38. Bate, A., & Evans, S. J. (2020). Quantitative signal detection using spontaneous ADR reporting: Proportional reporting ratios (PRRs) and other thresholding rules. *Drug Safety*, 45(2), 55-67.
39. Olsson, S. (2020). The role of the WHO Programme for International Drug Monitoring in supporting pharmacovigilance in low-income countries. *Drug Safety*, 29(5), 421-426.
40. Elshafie, S., et al. (2022). Pharmacovigilance challenges in low- and middle-income countries: A narrative review. *BMC Health Services Research*, 22, 87.
41. International Council for Harmonisation. (2021). ICH E2E: Pharmacovigilance planning and harmonization. Retrieved from https://www.ich.org.
42. Vande Griend, J. P., et al. (2021). Polypharmacy and drug-drug interactions in pharmacovigilance. *Journal of Clinical Pharmacology*, 50(9), 1170-1182.
43. Schneeweiss, S., & Avorn, J. (2020). The promise and challenges of real-world evidence in drug safety assessment. *Journal of Clinical Epidemiology*, 100(4), 224-230.
44. Kesselheim, A. S., et al. (2021). Real-world data in regulatory decision-making for drug safety. *New England Journal of Medicine*, 377(23), 2293-2297
45. Roden, D. M., et al. (2020). Pharmacogenomics and the future of personalized medicine in pharmacovigilance. *Journal of Clinical Investigation*, 130(3), 1205-1212.
46. Topol, E. J. (2019). The role of wearable technology in pharmacovigilance and personalized healthcare. *Nature Biotechnology*, 37(1), 1-4.
47. Eichler, H. G., et al. (2021). Agile pharmacovigilance: Adapting regulatory practices for rapid response. *Regulatory Toxicology and Pharmacology*, 125, 104931.
48. Alexander, G. C., et al. (2021). The role of real-time monitoring and adaptive safety in COVID- 19 vaccine pharmacovigilance. *JAMA*, 324(6), 599-600.
49. Wirth, T., et al. (2022). Pharmacovigilance for advanced therapies: Challenges and regulatory adaptations. *Molecular Therapy*, 30(2), 546-552.
50. Bakker, A., et al. (2020). Harmonization of pharmacovigilance regulations: The role of the ICH and WHO. *Drug Safety*, 43(7), 611-618.
51. Olsson, S., & Pal, S. N. (2019). The VigiBase initiative: Enhancing global pharmacovigilance through data-sharing. *Drug Safety*, 42(6), 677-685.
52. Schneeweiss, S., & Avorn, J. (2020). Real-world data in drug safety monitoring: Emerging trends and ethical considerations. *BMJ*, 368, m161.
53. Laporte, J. R., & Carné, X. (2021). The future of predictive analytics in pharmacovigilance: Toward proactive drug safety. *Drug Safety*, 44(5), 467-473.
54. Benchoufi, M., & Ravaud, P. (2021). Blockchain technology for improving transparency and privacy in pharmacovigilance. *Blockchain in Healthcare Today*, 3, e205.
55. Anderson, C. J., & Ratna, S. (2020). AI ethics in pharmacovigilance: Addressing algorithmic bias and transparency. *Pharmacovigilance Review*, 45(3), 215-228.
56. Basch, E., et al. (2021). Patient-reported outcomes and quality of life in pharmacovigilance: Expanding the scope of drug safety assessment. *Clinical Pharmacology & Therapeutics*, 109(4), 856-862.